Abstract:Background: In normal cells, homologous recombination (HR) is tightly regulated and plays an important role in the maintenance of genomic integrity and stability through precise repair of DNA damage. RAD51 is a recombinase that mediates homologous base pairing and strand exchange during DNA repair by HR. Our previous data in multiple myeloma and esophageal adenocarcinoma (EAC) show that dysregulated HR mediates genomic instability. Purpose of this study was to investigate role of HR in genomic instability, chemoresistance and immune dysregulation in solid tumors including colon and breast cancers. Methods: The GEO dataset were used to investigate correlation of RAD51 expression with patient survival and expression of various immune markers in EAC, breast and colorectal cancers. RAD51 was inhibited in cancer cell lines using shRNAs and a small molecule inhibitor. HR activity was evaluated using a plasmid-based assay, DNA breaks assessed by evaluating expression of γ-H2AX (a marker of DNA breaks) and p-RPA32 (a marker of DNA end resection) using Western blotting. Genomic instability was monitored by investigating micronuclei (a marker of genomic instability). Impact of RAD51 inhibitor and/or a DNA-damaging agent was assessed on viability and apoptosis in EAC, breast and colon cancer cell lines in vitro and in a subcutaneous tumor model of EAC. Impact of RAD51 inhibitor on expression profile was monitored by RNA sequencing. Results: Elevated RAD51 expression correlated with poor survival of EAC, breast and colon cancer patients. RAD51 knockdown in cancer cell lines inhibited DNA end resection and strand exchange activity (key steps in the initiation of HR) as well as spontaneous DNA breaks, whereas its overexpression increased DNA breaks and genomic instability. Treatment of EAC, colon and breast cancer cell lines with a small molecule inhibitor of RAD51 inhibited DNA breaking agent-induced DNA breaks and genomic instability. RAD51 inhibitor potentiated cytotoxicity of DNA breaking agent in all cancer cell types tested in vitro as well as in a subcutaneous model of EAC. Evaluation by RNA sequencing demonstrated that DNA repair and cell cycle related pathways were induced by DNA breaking agent whereas their induction either prevented or reversed by RAD51 inhibitor. In addition, immune-related pathways such as PD-1 and Interferon Signaling were also induced by DNA breaking agent whereas their induction prevented by RAD51 inhibitor. Consistent with these observations, elevated RAD51 expression also correlated with that of genes involved in inflammation and other immune surveillance. Conclusions: Elevated expression of RAD51 and associated HR activity is involved in spontaneous and DNA damaging agent-induced DNA breaks and genomic instability thus contributing to chemoresistance, immune dysregulation and poor prognosis in cancer. Therefore, inhibitors of RAD51 have great potential as therapeutic agents for EAC, colon, breast and probably other solid tumors.

The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid Tumors

Relationship between Targeting Rad51 and Cancer Treatment

Author Correction: the Bromodomain Containing Protein BRD-9 Orchestrates RAD51–RAD54 Complex Formation and Regulates Homologous Recombination-Mediated Repair

Emerging Cancer Therapeutic Opportunities Target DNA-repair Systems

Relationshin of Homologous Recombination Repair Factor Rad51 and Human Cancer

MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

Comprehensive Analysis of the Expression and Prognosis for RAD51 Family in Human Breast Cancer.

DNA Repair Pathways in Cancer Therapy and Resistance.

Targeting DNA Repair Pathways: Mechanisms and Potential Applications in Cancer Therapy

BRCA1: a Key Player at Multiple Stages of Homologous Recombination in DNA Double-Strand Break Repair

"Bridging the DNA divide": Understanding the interplay between replication- gaps and homologous recombination proteins RAD51 and BRCA1/2

DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy

Targeting DNA Double-Strand Break (DSB) Repair to Counteract Tumor Radio-resistance

DNA Damage and Its Role in Cancer Therapeutics

Untousling the Role of Tousled-like Kinase 1 in DNA Damage Repair

Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy

RAD52 resolves transcription-replication conflicts to mitigate R-loop induced genome instability